| Symbol | ANTX |
|---|---|
| Name | AN2 THERAPEUTICS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 1800 EL CAMINO REAL,SUITE D, MENLO PARK, California, 94027, United States |
| Telephone | +1 650 331-9090 |
| Fax | — |
| — | |
| Website | https://www.an2therapeutics.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001880438 |
| Description | AN2 Therapeutics Inc is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. The initial product candidate is epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial, or NTM, lung disease. Additional info from NASDAQ: |
Readnour Robin Shane 🔴 sold 16.1K shares of AN2 Therapeutics, Inc. (ANTX) at $6.07 Transaction Date: Sep 03, 2026 | Filing ID: 385511
Read moreWilliams Sarah Joanne 🔴 sold 272 shares of AN2 Therapeutics, Inc. (ANTX) at $5.53 Transaction Date: Sep 01, 2026 | Filing ID: 383697
Read moreFitzPatrick Margaret M 🟢 acquired 2.1K shares of AN2 Therapeutics, Inc. (ANTX) at $5.53 Transaction Date: Sep 01, 2026 | Filing ID: 380595
Read moreAN2 Therapeutics Presents Clinical and Translational Data Supporting Development of Epetraborole for Polycythemia Vera at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting
Read moreNew Form 3 - AN2 Therapeutics, Inc. <b>Filed:</b> 2026-08-27 <b>AccNo:</b> 0001193125-26-370943 <b>Size:</b> 3 KB
Read moreReadnour Robin Shane 🔴 sold 35.4K shares of AN2 Therapeutics, Inc. (ANTX) at $6.01 Transaction Date: Aug 17, 2026 | Filing ID: 357225
Read more📋 Readnour Robin Shane (Director) plans to sell 1.0M shares of AN2 Therapeutics, Inc. (at $6.01 each, total $6.1M) Filed: Aug 17, 2026 | ID: 000263
Read moreZakrzewski Joseph S 🔴 sold 405.9K shares of AN2 Therapeutics, Inc. (ANTX) Transaction Date: Aug 14, 2026 | Filing ID: 351801
Read more(30% Negative) AN2 THERAPEUTICS, INC. (ANTX) Reports Q3 2026 Financial Results
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07301320 | Epetraborole in Patients With Mycobacterium Abscessus Lung Disease | Phase2 | Mycobacterium Abscessus Infection | Recruiting | 2026-03-30 | 2028-05-01 | ClinicalTrials.gov |
| NCT07024589 | First-in-Human Trial of Oral AN2-502998 | Phase1 | Healthy Volunteers | Completed | 2025-08-04 | 2026-03-14 | ClinicalTrials.gov |
| NCT06089668 | An Observational Study to Evaluate Clinical Characteristics of Adult Patients W… | — | Melioidosis | Completed | 2023-11-01 | 2025-02-02 | ClinicalTrials.gov |
| NCT05995444 | A Study to Assess the Effects of Epetraborole on the QT Interval in Healthy Adu… | Phase1 | Healthy Volunteers | Completed | 2023-06-05 | 2023-08-03 | ClinicalTrials.gov |
| NCT05327803 | Study of Epetraborole in Patients With Treatment-refractory MAC Lung Disease | Phase2 | MAC Lung Disease | Terminated | 2022-05-20 | 2024-12-18 | ClinicalTrials.gov |
| NCT05283746 | A Study of Epetraborole Tablets in Subjects With Degrees of Renal Function | Phase1 | Renal Insufficiency | Completed | 2022-02-21 | 2022-06-27 | ClinicalTrials.gov |
| NCT04892641 | Phase 1 Study of Epetraborole Tablets | Phase1 | Healthy Volunteers | Completed | 2021-06-10 | 2022-02-26 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Placebo | Other | Phase PHASE2 | MAC Lung Disease | TERMINATED | NCT05327803 |
| Epetraborole | Other | Phase PHASE2 | MAC Lung Disease | TERMINATED | NCT05327803 |
| Placebo | Other | Phase PHASE2 | Mycobacterium Abscessus Infection | RECRUITING | NCT07301320 |
| Epetraborole | Other | Phase PHASE2 | Mycobacterium Abscessus Infection | RECRUITING | NCT07301320 |
| Placebo | Other | Phase PHASE2 | Mycobacterium Abscessus Infection | RECRUITING | NCT07301320 |
| Epetraborole | Other | Phase PHASE2 | Mycobacterium Abscessus Infection | RECRUITING | NCT07301320 |
| Placebo | Other | Phase PHASE2 | Mycobacterium Abscessus Infection | RECRUITING | NCT07301320 |
| Epetraborole | Other | Phase PHASE2 | Mycobacterium Abscessus Infection | RECRUITING | NCT07301320 |
| Placebo | Other | Phase PHASE2 | Mycobacterium Abscessus Infection | RECRUITING | NCT07301320 |
| Epetraborole | Other | Phase PHASE2 | Mycobacterium Abscessus Infection | RECRUITING | NCT07301320 |
| Placebo | Other | Phase PHASE2 | Mycobacterium Abscessus Infection | RECRUITING | NCT07301320 |
| Epetraborole | Other | Phase PHASE2 | Mycobacterium Abscessus Infection | RECRUITING | NCT07301320 |
| Placebo | Other | Phase PHASE2 | Mycobacterium Abscessus Infection | RECRUITING | NCT07301320 |
| Epetraborole | Other | Phase PHASE2 | Mycobacterium Abscessus Infection | RECRUITING | NCT07301320 |
| Placebo | Other | Phase PHASE2 | Mycobacterium Abscessus Infection | RECRUITING | NCT07301320 |
| Epetraborole | Other | Phase PHASE2 | Mycobacterium Abscessus Infection | RECRUITING | NCT07301320 |
| Placebo | Other | Phase PHASE2 | Mycobacterium Abscessus Infection | RECRUITING | NCT07301320 |
| Epetraborole | Other | Phase PHASE2 | Mycobacterium Abscessus Infection | RECRUITING | NCT07301320 |
| Epetraborole | Other | Phase PHASE1 | Renal Insufficiency | COMPLETED | NCT05283746 |
| Moxifloxacin | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05995444 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05995444 |
| Epetraborole | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05995444 |
| Epetraborole and matching placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05995444 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04892641 |
| Epetraborole | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04892641 |
| Placebo | Other | Phase PHASE2 | MAC Lung Disease | TERMINATED | NCT05327803 |
| Epetraborole | Other | Phase PHASE2 | MAC Lung Disease | TERMINATED | NCT05327803 |
| Observational Study | Other | Preclinical | Melioidosis | COMPLETED | NCT06089668 |
| Placebo | Other | Phase PHASE2 | Mycobacterium Abscessus Infection | NOT_YET_RECRUITING | NCT07301320 |
| Epetraborole | Other | Phase PHASE2 | Mycobacterium Abscessus Infection | NOT_YET_RECRUITING | NCT07301320 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT07024589 |
| AN2-502998 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT07024589 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT07024589 |
| AN2-502998 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT07024589 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT07024589 |
| AN2-502998 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT07024589 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT07024589 |
| AN2-502998 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT07024589 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT07024589 |
| AN2-502998 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT07024589 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT07024589 |
| AN2-502998 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT07024589 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT07024589 |
| AN2-502998 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT07024589 |
| AN2-502998 | DRUG | Phase PHASE1 | Healthy Volunteers | RECRUITING | NCT07024589 |
| Observational Study | OTHER | Preclinical | Melioidosis | COMPLETED | NCT06089668 |
| Moxifloxacin | DRUG | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05995444 |
| Epetraborole and matching placebo | DRUG | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05995444 |
| Placebo | DRUG | Phase PHASE2 | Mycobacterium Abscessus Infection | NOT_YET_RECRUITING | NCT07301320 |
| Epetraborole | DRUG | Phase PHASE2 | Mycobacterium Abscessus Infection | NOT_YET_RECRUITING | NCT07301320 |